Table 1.
Demographic and clinical characteristics of study patients
| Variables | Patients received metformin (n = 32) | Placebo group (n = 31) | p-value |
|---|---|---|---|
| Male/Female |
17/15 |
14/17 |
0.352 |
| Age (y) |
51.9 ± 10.9 |
55.2 ± 14.0 |
0.306 |
| BMI (kg/m²) |
32.6 ± 5.8 |
31.5 ± 5.6 |
0.410 |
| Current smokers, n (%) |
4 (12.5%) |
2 (6.5%) |
0.391 |
| Hypertension, n (%) |
15 (46.9%) |
15 (48.4%) |
0.599 |
| Dyslipidemia, n (%) |
21 (65.6%) |
14 (45.2%) |
0.079 |
| DM/IFG, n (%) |
6/14(18.8/43.8%) |
2/13 (6.5/41.9%) |
0.128 |
| Concomitant medication: |
|
|
|
| Antidiabetic treatment (%) |
6 (18.8%) |
2 (6.5%) |
0.194 |
| Statins (%) |
18 (56.3%) |
11 (35.5%) |
0.079 |
| ACEIs/ARBs (%) |
9 (28.1%) |
9 (29.0%) |
0.609 |
| Diuretics (%) |
1 (3.1%) |
6 (19.4%) |
0.104 |
| B-blockers (%) |
9 (28.1%) |
10 (32.3%) |
0.784 |
| CCB-blockers (%) |
5 (15.6%) |
8 (25.8%) |
0.351 |
| Aspirin (%) |
13 (40.6%) |
9 (29.0%) |
0.292 |
| Baseline systolic BP (mm/Hg) |
138.8 ± 17.6 |
133.6 ± 18.1 |
0.258 |
| Baseline diastolic BP (mm/Hg) |
80.1 ± 9.8 |
74.6 ± 13.5 |
0.072 |
| Baseline heart rate (bts/min) |
68.6 ± 12.3 |
62.9 ± 8.4 |
0.034 |
| Baseline fasting glucose (mg/dl) |
131.8 ±51.3 |
98.3 ± 14.8 |
0.001 |
| Baseline total cholesterol (mg/dl) |
184.5 ± 43.3 |
191.1 ± 37.0 |
0.523 |
| Baseline LDL Cholesterol (mg/dl) |
110.4 ± 37.9 |
112.7 ± 34.2 |
0.811 |
| Baseline HDL-cholesterol (mg/dl) |
42.6 ± 13.0 |
48.2 ± 15.2 |
0.123 |
| Baseline triglycerides (mg/dl) |
185.5 ± 112.0 |
143.1 ± 63.2 |
0.070 |
| Baseline hs-CRP (mg/dl) |
0.9 ± 1.1 |
0.9 ± 1.4 |
0.969 |
| Baseline AST (U/l) |
28.9 ± 16.8 |
28.0 ± 8.2 |
0.796 |
| Baseline ALT (U/l) |
38.0 ± 29.9 |
32.6 ± 15.3 |
0.377 |
| Baseline ALP (U/l) |
67.7 ± 17.0 |
72.2 ± 23.5 |
0.386 |
| Baseline creatinine (mg/dl) |
0.9 ± 0.1 |
0.9 ± 0.2 |
0.723 |
| Baseline urea (mg/dl) |
32.0 ± 10.0 |
32.0 ± 9.0 |
1.000 |
| Baseline adiponectine (ng/ml) |
6130.5 ± 2872.6 |
9156.3 ± 6365.2 |
0.020 |
| Baseline AI (%) | 31.4 ± 11.1 | 30.0 ± 10.7 | 0.628 |